{"protocolSection":{"identificationModule":{"nctId":"NCT00276185","orgStudyIdInfo":{"id":"CHU63-0003"},"organization":{"fullName":"University Hospital, Clermont-Ferrand","class":"OTHER"},"briefTitle":"HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke","officialTitle":"Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke"},"statusModule":{"statusVerifiedDate":"2011-01","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-12"},"primaryCompletionDateStruct":{"date":"2009-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2009-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2006-01-12","studyFirstSubmitQcDate":"2006-01-12","studyFirstPostDateStruct":{"date":"2006-01-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-01-18","lastUpdatePostDateStruct":{"date":"2011-01-19","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Pr Franck DURIF","oldOrganization":"CHU Clermont-Ferrand"},"leadSponsor":{"name":"University Hospital, Clermont-Ferrand","class":"OTHER"},"collaborators":[{"name":"J. Rebeyrol Hospital in Limoges","class":"UNKNOWN"},{"name":"Rennes University Hospital","class":"OTHER"},{"name":"Center of Physical Medicine and Rehabilitation (Notre Dame de Lourdes Center in Rennes)","class":"UNKNOWN"},{"name":"Saint Jacques Hospital in Nantes","class":"UNKNOWN"},{"name":"Centre Hospitalier Universitaire de Saint Etienne","class":"OTHER"},{"name":"Centre Régional de Département de médecine physique et réadaptation CHU-C3RF in Angers","class":"UNKNOWN"},{"name":"Centre Hospitalier Universitaire de Besancon","class":"OTHER"}]},"descriptionModule":{"briefSummary":"Botulinum toxin produced beneficial effects in spasticity in the hemiplegic upper limb. This study will test if botulinum toxin injections at earlier phases (\\<or = 3 months) in spasticity improve functional and motor tests compared with late injections (\\>or = 6 months)."},"conditionsModule":{"conditions":["Hemiplegia"],"keywords":["spasticity ;","Botulinum toxin ;","Upper limb ;","motor function.","spastic hemiplegia after stoke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":180,"type":"ESTIMATED"}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"Time delay treatment of botulinum toxin"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Deficiency, incapacity, handicap : Frenchay Arm test(post stroke arm function); Enjalbert test;"},{"measure":"Box and blocks test"},{"measure":"Enjalbert test"},{"measure":"Modified Ashworth scale (upper limb)"},{"measure":"Functional Independence Measure"},{"measure":"Fugl-Meyer upper limb test"},{"measure":"Clinical Global Impression (CGI)"},{"measure":"36-Item Short Form (SF-36) quality of life"}],"secondaryOutcomes":[{"measure":"Range of pain"},{"measure":"Individual functional kinesitherapy"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Minimum age 18\n* Spastic hemiplegia after ischemic stroke (carotid occlusion) within the past 3 months.\n* Antispasticity medication stabilized for the last 30 days\n* Severe cognitive impairment such that patient is unable to provide scale assessment.\n* Significant spasticity impeding improvement by re-education for 2 months or less\n* Lack of muscular retraction defined by a minimal range of articular motion as :\n\n  * finger : complete extension and rolling up\n  * wrist : extension 40°/flexion : 45°\n  * elbow : extension - 10°/flexion : 120°\n  * shoulder : Enjalbert score 2 or more\n* Antagonist muscles (to spasticity) activity score 1 or more\n* Social Security benefits\n\nExclusion Criteria:\n\n* Ischemic stroke thought to be due to basilar or vertebral vessel occlusion\n* Known motor neuron or neuromuscular junction disease, disorders in which pain limits the ability to inject muscles (algodystrophy)\n* Absence of mobility in proximal part of upper limb that does not predict a functional gain\n* Minor stroke with non-disabling deficit or rapidly improving motor symptoms\n* other serious illness, e.g. severe hepatic, cardiac, or renal failure ; acute myocardial infarction ; or a complex disease that may confound treatment assessment\n* Treatment of spasticity by previous administration of botulinum toxin, if known\n* Known allergy to botulinum toxin\n* Currently participating in other research studies","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Franck Durif","role":"CONTACT","phone":"(33) 04 73 750 750"}],"overallOfficials":[{"name":"Franck Durif","affiliation":"University Hospital, Clermont-Ferrand","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Clermont-Ferrand University Hospital","status":"RECRUITING","city":"Clermont-Ferrand","state":"Auvergne","zip":"63000","country":"France","contacts":[{"name":"Franck Durif","role":"CONTACT","phone":"(33) 04 73 750 750"}],"geoPoint":{"lat":45.77966,"lon":3.08628}}]},"referencesModule":{"references":[{"pmid":"10946168","type":"RESULT","citation":"Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage. 2000 Jul;20(1):44-9. doi: 10.1016/s0885-3924(00)00146-9."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000006429","term":"Hemiplegia"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000010243","term":"Paralysis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9205","name":"Hemiplegia","asFound":"Hemiplegia","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spastic","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M12847","name":"Paralysis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}